Indium-111 capromab pendetide in the management of recurrent prostate cancer

Expert Review of Anticancer Therapy

Volumn 8, Issue 2, 2008, Pages 175-181

  Manyak, Michael J ^a,b  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

Capromab pendetide; ProstaScint ; Prostate specific membrane antigen; Radioimmunoscintigraphy

Indexed keywords

BIOLOGICAL MARKER; CAPROMAB PENDETIDE IN 111; PROSTATE SPECIFIC MEMBRANE ANTIGEN;

ANDROGEN THERAPY; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD PRESSURE; CANCER GROWTH; CANCER LOCALIZATION; CANCER RECURRENCE; DIAGNOSTIC ACCURACY; FEVER; HEADACHE; HIGH RISK PATIENT; HUMAN; ISOTOPE LABELING; LYMPH NODE METASTASIS; OUTCOME ASSESSMENT; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PRURITUS; RASH; RISK ASSESSMENT; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TASTE;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; COMBINED MODALITY THERAPY; HUMANS; IMMUNOHISTOCHEMISTRY; INDIUM RADIOISOTOPES; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TREATMENT OUTCOME;

EID: 40749110135     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.8.2.175     Document Type: Article

References (41)

1. Jemal A, Siegel R. Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J. Clin. 57, 43-66 (2007).
2. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351, 15012-1512 (2004).
3. Eisenberger MA, Blumenstein BA, Crawford ED et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N. Engl. J. Med. 339, 1036-1042 (1998).
4. Berthold DR, Sternberg CN, Tannock IF. Management of advanced prostate cancer after first-line chemotherapy. J. Clin. Oncol. 23, 8247-8252 (2005).
5. Partin AW, Kattan MW, Subong EN et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 277, 1445-1451 (1997).
6. Freedland SJ, Humphreys EB, Mangold LA et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294, 433-439 (2005).
7. Krupski TL, Kwan L, Afifi AA, Litwin MS. Geographic and socioeconomic variation in the treatment of prostate cancer. J. Clin. Oncol. 23, 7881-7888 (2005).
8. Oh WK. The evolving role of estrogen therapy in prostate cancer. Clin. Prostate Cancer 1, 81-89 (2002).
9. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 351, 1513-1520 (2004).
10. Serafini AN, Houston SJ, Resche I et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J. Clin. Oncol. 16, 1574-1581 (1998).
11. Stone NN, Stock RG, Unger P. Laparoscopic pelvic lymph node dissection for prostate cancer: comparison of the extended and modified techniques. J. Urol. 158, 1891-1894 (1997).
12. Heidenreich A, Varga Z, Von KR. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J. Urol., 167, 1681-1686 (2002).
13. Bader P, Burkhard FC, Markwalder R, Studer UE. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J. Urol. 169, 849-854 (2003).
14. Murray SK, Breau RH, Gulia AK, Gupta R. Spread of prostate carcinoma to the perirecral lymph node basin: analysis of 112 rectal resections over a 10-year span for primary rectal adenocarcinoma. Am. J. Surg. Pathol. 28, 1154-1162 (2004).
15. Harisinghani MG, Barentsi J, Hahn PF et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N. Engl. J. Med. 348, 2491-2499 (2003).
16. Oehr P, Bouchelouche K. Imaging of prostate cancer. Curr. Opin. Oncol. 19, 259-264 (2007).
17. 18F-FDG in patients with progressive, metastatic prostate cancer. J. Nucl. Med. 45, 366-373 (2004).
18. Israeli RS, Powell CT, Corr JG, Fair WR, Heston WD. Expression of the prostate-specific membrane antigen. Cancer Res. 54, 1907-1811 (1994).
19. Wright GL Jr, Grob BM, Haley C et al. Upregulati6n of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 48, 326-334 (1996).
20. Schulke N, Varlamova OA, Donovan GP et al. The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy. Proc. Natl Acad. Sci USA 100, 12590-12595 (2003).
21. Manyak MJ, Hinkle GH, Olsen JO et al. Immunoscintigraphy with indium-111-capromab pendetide: evaluation before definitive therapy in patients with prostate cancer. Urology 54, 1058-1063 (1999).
22. Hinkle GH, Burgers JK, Neal CE et al. Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide. Cancer 83, 739-747 (1998).
23. Sodee DB, Nelson AD, Faulhaber PF, Maclennan GT, Resnick MI, Bakale G. Update on fused capromab pendetide imaging of prostate cancer. Clin. Prostate Cancer 3, 230-238 (2005).
24. 111indium-capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients. Cancer 85, 1586-1592 (1999).
25. Ross JS, Sheehan CE, Fisher HA et al. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin. Cancer Res. 9, 6357-6362 (2003).
26. Perner S, Hofer MD, Kim R et al. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum. Pathol. 38, 696-701 (2007).
27. 111In-capromab pendetide (ProstaScint) scan as pretreatment radiotherapy for rising prostate-specific antigen after radical prostatectomy for prostate cancer. Int. J. Rad. Oncol. Biol. Phys. 67, 834-840 (2007).
28. Wong TZ, Turkington TG, Polascik TJ, Coleman RE. ProstaScint (capromab pendetide) imaging using hybrid gamma camera-CT technology. Am. J. Roentgenol. 184, 676-680 (2005).
29. Schettino, CJ, Kramer EL, Noz ME, Taneja S, Padmanabhan P, Lepor H. Impact of fusion of indium-111 capromab pendetide volume data sets with those from MRI or CT in patients with recurrent prostate cancer. Am. J. Roentgenol. 183, 519-524 (2004).
30. 111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The ProstaScint Study Group. J. Urol. 159, 2041-2046 (1998).
31. Kahn D, Williams RD, Hasemn MK, Reed NL, Miller SJ, Gerstbrein J. Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after filed radical prostatectomy. J. Clin. Oncol. 16, 284-289 (1998).
32. Thomas CT, Bradshaw PT, Pollock BH et al. Indium-111-capromab pendetide radioimmunoscintigraphy and Prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy. J. Clin. Oncol. 21, 1715-1721 (2003).
33. 111indium-capromab pendetide imaging for assesing biochemical figure after radical prostatectomy. J. Urol. 172, 133-136 (2004).
34. Jani AB, Blend MJ, Hamilton R et al. Radioimmunoscintigraphy for postprostatectomy radiotherapy: analysis of toxicity and biochemical control. J. Nucl. Med. 45, 1315-1322 (2004).
35. Haseman MK, Rosenthal SA, Kipper SL, Trout JR, manyak MJ. Central abdominal uptake of indium-111 capromab pendetide (ProstaScint) predicts for poor prognosis in patients with prostate cancer. Urology 70, 303-308 (2007).
36. Ellis RJ, Zhou H, Kim EY et al. Biochemical disease-free survival rates following definitive low-dose-rate prostate brachytherapy with dose escalation to biologic target volumes identified with SPECT/CT capromab pendetide. Brachytherapy 6, 16-25 (2007).
37. Ellis RJ, Zhou H, Kaminsky DA et al. Rectal morbidity after permanent prostate brachytherapy with dose escalation to biologic target volumes identified by SPECT/CT fusion. Brachytherapy 6, 149-156 (2007).
38. Schild SE, Vora SA, Wong WW et al. The use of fused ProstaScint CT scans in planning IMRT for prostate cancer. Presented at: ASCO Prostate Cancer Symposium. Orlando, FL, USA, February 23, 2007 (Abstract 363).
39. Keane TE, Rosner IL, Wingo MS, McLeod DG. The emergence of radioimmunoscintigraphy for prostate cancer. Rev. Urol. 8(Suppl. 1), S20-S28 (2006).
40. ProstaScint®, prescribing information. Cytogen Corp., NJ, USA (1997).
41. 111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer. Clin. Cancer Res. 11, 7454-7461 (2005).